|
Obecabtagene autoleucel Clinical Trials
3 actively recruiting trials across 3 locations
No change since May 2026
Also known as: Obe-cel
Pipeline
Phase 2: 3
Top Sponsors
- Memorial Sloan Kettering Cancer Center1
- M.D. Anderson Cancer Center1
- Autolus Limited1
Gilbert, Arizona1 trial
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis
Banner MD Anderson Cancer Center at Canyon Springs
Phase 2
Basking Ridge, New Jersey1 trial
A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Phase 2
Houston, Texas1 trial
Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
The University of Texas M. D. Anderson Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.